Article Text

Download PDFPDF
Measuring patient experience of Cytosponge using the Newcastle ENDOPREM
  1. Laura Jane Neilson1,2,
  2. Rebecca C Fitzgerald3,4,
  3. Jennifer Deane2,
  4. Irene Debiram-Beecham3,
  5. Linda Sharp2,
  6. Colin J Rees1,2
  1. 1 Department of Gastroenterology, South Tyneside District Hospital, South Shields, UK
  2. 2 Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
  3. 3 Early Cancer Institute, University of Cambridge, Cambridge, UK
  4. 4 Early Detection Programme, CRUK Cambridge Centre, Cambridge, UK
  1. Correspondence to Dr Laura Jane Neilson, Department of Gastroenterology, South Tyneside District Hospital, South Shields, NE34 0PL, UK; l.neilson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Cytosponge is an exciting novel technology for oesophageal pathology diagnosis. Uses include screening for Barrett’s oesophagus, Barrett’s surveillance and triage of patients with chronic reflux symptoms. Cytosponge performs well in Barrett’s oesophagus diagnosis, with a specificity of >92% and sensitivity of 80% in intention-to-treat analyses in a case–control study.1 Furthermore, a cluster-randomised controlled trial demonstrated that offering Cytosponge to individuals with chronic reflux increased Barrett’s diagnoses by over 10 times compared with usual care.2

The need to reduce the burden on endoscopy services (exacerbated by the COVID-19 pandemic) expedited the pilot implementation of Cytosponge into national care pathways. Cytosponge can prioritise upper gastrointestinal (GI) endoscopy with high sensitivity and specificity for high grade dysplasia and early cancer.3 UK policy-makers strongly support real-world implementation studies with independent evaluation.

Patient experience is a crucial marker of quality of GI procedures and impacts patient attendance and reattendance. All patient-reported experience measures should be patient centred; derived from and completed by patients.4 Previous GI endoscopy patient experience …

View Full Text


  • LS and CJR are joint senior authors.

  • Contributors CR, RCF, LS and LJN conceived and designed the study. ID-B and JD undertook participant recruitment. JD undertook qualitative interviews. JD, LS and LJN undertook qualitative analysis. JD, LS, LJN and CR adapted PREM according to analysis. All authors contributed to this letter.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests LJN, LS and CR have received grant funding from Medtronic. LS and CR have received grant funding from 3D Matrix solutions. CJR has received grant funding from ARC medical, Norgine and Olympus medical. He was an expert witness for ARC medical and Olympus medical. RCF is named on patents related to Cytosponge and associated assays that have been licensed to Covidien (now Medtronic). RCF is a founder and <8% shareholder of Cyted Ltd. ID-B and JD have no conflicts to declare.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.